Thursday 25 April 2024

Controlled Substance

A controlled substance is generally a drug or chemical whose manufacturepossession and use is regulated by a government, such as illicitly used drugs or prescription medications that are designated by law. Some treaties, notably the Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, provide internationally agreed-upon "schedules" of controlled substances, which have been incorporated into national laws; however, national laws usually significantly expand on these international conventions.

Some precursor chemicals used for the production of illegal drugs are also controlled substances in many countries, even though they may lack the pharmacological effects of the drugs themselves. Substances are classified according to schedules and consist primarily of potentially psychoactive substances and anabolic steroids. The controlled substances do not include many prescription items such as antibiotics.

Laws and enforcement

In the United States, the Drug Enforcement Administration is the federal government agency responsible for suppressing illegal drug use and distribution by enforcing the Controlled Substances Act, which regulates both the drugs themselves and certain precursors. Some U.S. states have additional restrictions for substances which might or might not be regulated by the federal government. During the Obama Administration, the federal government also voluntarily suspended enforcement of federal laws restricting marijuana where people were operating in compliance with state law.

Some states in the U.S. have statutes against health care providers self-prescribing and/or administering substances listed in the Controlled Substance Act schedules. This does not forbid licensed providers from self-prescribing medications not on the schedules.

The term Controlled Drug in the United Kingdom (CD) is used for substances governed by the Misuse of Drugs Act 1971.[2] Other national drug prohibition laws include the Controlled Drugs and Substances Act (Canada) and the Misuse of Drugs Act 1975 (New Zealand), among many others.

Within Europe controlled substance laws are legislated at the national rather than by the EU itself, with significant variation between countries in which and how chemicals are classified as controlled. Only drug precursor laws are legislated for at the European level. 


Use in research

A common misunderstanding amongst researchers is that most national laws allow the use of small amounts of a controlled substance for non-clinical / non-in vivo research without licences. A typical use case might be having a few milligrams or microlitres of a controlled substance within larger chemical collections (often 10K's of chemicals) for in vitro screening. Researchers often believe that there is some form of “research exemption” for such small amounts. This incorrect view may be further re-enforced by R&D chemical suppliers often stating and asking scientists to confirm that anything bought is for research use only.

A further misconception is that controlled substances laws simply list a few hundred substances (e.g. MDMA, Fentanyl, Amphetamine, etc.) and compliance can be achieved via checking a CAS number, chemical name or similar identifier. However, the reality is that most countries enact “generic statement" or “chemical space” laws, which aim to control all chemicals similar to the “named” substance. These either provide detailed descriptions similar to Markushes, or simply state analogues are also controlled. In addition, control of most named substances is extended to control of all of their ethers, esters, salts and stereoisomers.

Due to this complexity in legislation the identification of controlled chemicals in research is often carried out computationally, either by in house systems maintained a company's sample logistics department or by the use commercial software solutions.[3] Automated systems are often required as many research operations can often have chemical collections running into 10Ks of molecules at the 1–5 mg scale, which are likely to include controlled substances, especially within medicinal chemistry research. These may not have been controlled when created, but they have subsequently been declared controlled

Known research exemptions

Source:[4]

Switzerland

Has limited exemptions to some Directory E substances, but which substances are covered and what the exemption allows depends on the substance, for example compounds similar to Fentanyl allow for “Von der Kontrolle ausgenommen ist die industrielle und die wissenschaftliche Verwendung. Der private Gebrauch ist nicht von der Kontrolle ausgenommen” or “Excluded from the control is the industrial and scientific use. Private use is not exempt from the control.” The exemption wording for Cyclohexylphenols is “Cyclohexylphenole sind von der Kontrolle nach den Kapiteln 5 und 6 der Verordnung über die Betäubungsmittelkontrolle vom 25. Mai 2011 ausgenommen, wenn sie von Unternehmen mit einer Betriebsbewilligung für den Umgang mit kontrollierten Substanzen des Verzeichnisses e industriell eingesetzt werden. Für Substanzmengen bis zu 100 g benötigen diese Unternehmen keine Ein- oder Ausfuhrbewilligung.” or “Cyclohexylphenols are exempted from the control under Chapters 5 and 6 of the Narcotics Control Ordinance of 25 May 2011 if they are used industrially by undertakings holding an operating license for the handling of controlled substances in Inventory e. For substance quantities of up to 100g, these companies do not require an import or export license”. In addition, import or export authorization is not required in case of controlled substances for analytical purpose in concentrations up to 1 mg/ml. (Art 23, Abs. 2b, BetmKV) [5]

Further qualifications apply e.g. yearly limits as well individual shipment limits


United Kingdom

There are no specific research exemptions in the Misuse of Drugs Act 1971. However, the associated Misuse of Drugs Regulations 2001[6] does exempt products containing less than 1 mg of a controlled substance (1 ug for lysergide and derivatives) so long as a number of requirements are met, including that it cannot be recovered by readily applicable means, does not pose a risk to human health and is not meant for administration to a human or animal.

Although this does at first seem to allow research use, in most circumstances the sample, by definition, is “recoverable” - in order to prepare it for use the sample is ‘recovered’ into an assay buffer or solvent such as DMSO or water. In 2017 the Home Office also confirmed that the 1 mg limit applies to the total of all preparations across the entire container in the case of sample microtitre plates.  Given this, most companies and researchers choose not to rely on this exemption.

According to Home Office licensing, "University research departments generally do not require licences to possess and supply drugs in schedule 2 drugschedule 3 drugschedule 4 drug part I, part II and schedule 5, but they do require licences to produce any of those drugs and to produce, possess and/or supply drugs in schedule 1".

United States of America

In the US no general research exemptions are  known to exist, at least at the federal level and the Controlled Substances Act.

Germany

The Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) / (Law on the Traffic in Narcotic Drugs (Narcotics Act - BtMG) has a partial exemption that might apply to certain research areas.

For each schedule the act allows for

the preparations of the substances listed in this Appendix if they are not

a)      without being applied to or in the human or animal body, for diagnostic or analytical purposes only, and their content of one or more anesthetics not exceeding 0.001 per cent, or isotope-modified in the preparations, or

b)      are particularly excluded;

die Zubereitungen der in dieser Anlage aufgeführten Stoffe, wenn sie nicht

a)      ohne am oder im menschlichen oder tierischen Körper angewendet zu werden, ausschließlich diagnostischen oder analytischen Zwecken dienen und ihr Gehalt an einem oder mehreren Betäubungsmitteln jeweils 0,001 vom Hundert nicht übersteigt oder die Stoffe in den Zubereitungen isotopenmodifiziert oder

b)      besonders ausgenommen sind;

The exact percentage various for each schedule. Also whether the ‘0.001%’ allows the rest to be an assay solvent or medium, or whether a licence is needed if you have some solid, e.g. 1 mg of sample before its diluted is not clear

Saturday 20 April 2024

Digital Prescriptions are the solution

Handwritten prescriptions in India often pose significant risks due to their potential for misinterpretation. The diverse linguistic landscape of India, with multiple languages and scripts, adds to the complexity of deciphering these prescriptions accurately. Common issues include illegible handwriting, which can lead to confusion between drugs with similar names or incorrect dosing instructions. This is particularly problematic given the wide range of medications available and the critical importance of precise dosages.

Moreover, handwritten prescriptions sometimes lack essential information such as patient history, allergies, or specific instructions for drug administration. In a healthcare environment where pharmacists play a key role in the safe dispensing of medications, these omissions can lead to serious health risks.

The situation calls for a more robust system, possibly incorporating digital prescriptions, which can ensure clarity, accuracy, and traceability. Standardizing prescription formats and embracing electronic health records could greatly mitigate the risks associated with handwritten prescriptions, leading to safer and more effective patient care in the Indian context.

Consumer awareness towards medicine and its quality

AMR


One of the major health issues facing the whole world today is Antimicrobial Resistance (AMR). And this alone is not the health crisis of today's generation, because it is not handled on time, it will be the biggest health crisis for the next generation too. Experts in the field have already hoisted a red flag on the critical situation of a world without antibiological if necessary steps are not taken immediately. Even though AMR emerges naturally over time, blind use of antibiotics is one of the major reasons for AMR emerging. The hard fact is that antibiotic abuse and overuse is at risk of decades of medical advancements. It has often been found that over-the-counter availability cases of these lifesaving drugs makes worse as people buy antibiotic medicines for virus-causing diseases instead of bacteria. When antibiotics are so readily available, it's not necessary to take the necessary care. Another fact that AMR burden falls inequality on low and moderate income countries, where healthcare systems are overloaded and resources have increased. The seriousness of the situation that some reports can be estimated that India is likely to cause nearly 2 million deaths from AMR by 2050 as the country has the highest rate of antibiological immunity in bacteria generally causing infection. And the health facilities.

Naturally, the global community has declared AMR as a public health crisis and regulators around the world, along with Indian regulators, have already started measures to solve this problem at the war level as regulators seize this critical situation. Recently, the National Medical Commission has decided to create a general module on AMR control which will improve awareness and understanding of AMR among pregraduate, postgraduate medical students and teaching professionals in medical colleges. This is an appropriate step because there are some atrocious prescriptions from some doctors that write more antibiologically and unnecessarily. Commission's action in this regard is part of efforts to implement the National Action Scheme (NAP) on AMR which aims to reduce the spread of AMR in the country. Recently, the All India Chemist and Distributors Federation, an association of drug distributors and retailers across the country, has given an instruction to the government that the period or expiration date of use is required on the land of treatment use. Doctors prescription to stop the spread of AMR due to their overuse. The fact is that most often, people use old prescription for similar symptoms as previous diseases and take medications the doctor prescribed five years ago or six years ago. Doctors write the same antibiological at a specific time for a specific disease, but they still use the same prescription when the patient has the same disease after five years or six years. Undoubtedly, the medicine used by the patient five years ago may not be affected by his current disease. While the situation gets serious, experts have appealed drug regulators to play a vital role in countering the threat, as the main reason is misuse, overuse and less use of antibiotics. Regulators should literally implement a schedule H and H1 of drugs and cosmetics to stop OTC sales of antibiotics. Regulators shouldn't feel short in making sure pharmacists and hospitals are following the laws and selling schedule H and H1 drugs only on qualified doctors prescription. Delivering without pharmacists and selling without prescription should be stopped immediately to cover the risk of AMR. Government should pay attention to all these instructions and act fast as AMR is a ticking time bomb.
https://chat.whatsapp.com/ESnQA4VD8aRL8I87NxhJ73 

#QualityAssuranceToPatients - #QRCodeWhy not create a #QRCode on Medicine label to get Batch Quality Report?It would also prevent Black-Sheep Cos selling untested or failed batches.#Everyone

#QualityAssuranceToPatients - #QRCode

Why not create a #QRCode on Medicine label to get Batch Quality Report?

It would also prevent Black-Sheep Cos selling untested or failed batches.

#Everyone

A different POV : Think over🤔Professionals support Drugs Act & Pharmacy Act..But, Both neither support Profession nor professionals!

A different POV : 

Think over🤔

Professionals support Drugs Act & Pharmacy Act..

But, 
Both neither support Profession nor professionals!

A different POV : Pharmacists have failed to impress professionally and leave professional footprints in Health Sector

A different POV : Pharmacists have failed to impress professionally and leave professional footprints in Health Sector . Therefore requirement of a new course like Pharm D / Pharma D (PB), which will produce professionals called Pharmacist and Pharmacotherapist. 

Thursday 22 February 2024

So many regulatory bodies and governing bodies in pharmacy education: whims of my mind

PCI(Pharmacy Council Of India) and AICTE(All India Council for technical education) are the governing bodies in the pharmacy education , keeping in mind the compounding and dispensing as well as the technical aspects involved in Pharmaceutical Engineering .

Now with the advent of Pharm D course in pharmacy, which is clinically oriented 6 years course in pharmacy and the syllabus is designed such as  first 3 years are same as B.Pharm ( compounding and dispensing oriented) and next 2 years are same as MD Pharmacology (medically and clinically oriented) and 1 year of internship in an attached (minimum- 300 beded) hospital , one may expect MCI (medical council of India) to get into the thick of the things/matters.

As it requires an affiliation with a  hospital( minimum 300 beded), to get approval for an pharmaceutical institute from PCI to conduct the course , one must expect MCI(medical council of India) also to get involved as a regulatory and governing body.

PCI governs courses like : D.Pharm
                                         B.Pharm
                                        Pharm D and Pharm D(PB)

AICTE governs courses like : B.Pharm( jointly with PCI)
                                              M.Pharm

Now one must expect AICTE,PCI and MCI may jointly govern : Pharm D and Pharm D(PB)

But no, its not a rational thinking on my part. MCI will get involve only when the course is a medical one or may be when the professional doctor is dealing with a body part.
So, its fair enough that MCI is not involved into these matters.

                                             

Sunday 11 February 2024

PHARMACIST IN HEALTHCARE/PHARMACARE

PHARMACIST IN HEALTHCARE.

Unless Indian healthcare service and infrastructure is made inclusive of pharmacy and pharmacists service, there is no scope for pharmacist in healthcare

Monopoly-is this the motto behind delayed subject addition issue?

Who are the stakeholders for pharmD(PB)? Who will protect our rights ?who will see our benefits are taken care ofinstead of thinking about others/PharmD , let us think about ourselves /PharmD(PB).Once you are happy then only you are able to keep others happy isnt it?one official association should be made there concerning the benefits of PharmD(PB) and for the protection of rights of pharmd(PB) students, who will take care of any issues related with PharmD(PB).whats ur say?Any talk related with the betterment of pharmD(PB) students should be encouraged here.Friends,my opinions are entirely my own and I can recommend them. I agree with you on some of the points u made here on this post, but my issue is that there should be some uniformity through out the country regarding the syllabus of a PharmD/PharmD(PB) curriculum.thats all i have to say.When I paid an amount as fees in my college to get some degree and study a curriculum, i just want to make it sure that i get the best out of it. My concern is only that the fundamental, basic ,core subjects like pathophysiology, hospital Pharmacy and community pharmacy must get added in the PharmD(PB) syllabus,this year before i pass out. I am not blaming entirely to organizations like PCI and universities for this.When I took admission in PharmD(PB), I was ignorant about this syllabus issue, but now today when i came to know about this, i want to rectify it and make other pharmD(PB) students like me ,aware about the same. However I guess some blame also goes to the abovesaid parent organizations, as when they are launching and approving a course, they should ensure that all is well, because i expect an organization's vision should be much broader than an individual's.It seems as if the Pharm- D (PB) syllabus has been structured by some beheaded ghost. However as they say you are responsible for your own life. I am not against PharmD regular, I wish them all the best and all the luck. But I am worried about myself and PharmD(PB) syllabus . There is nothing wrong in it!!!Now a days when it snows or rains, 5% of people go outside and play and enjoy it ; while 95% make a Facebook status about it.
Purpose is get aware and do something about the issue, just dont sit there doing nothing.
On pharmaceutical events and on Facebook also I see students worrried and talking about trival issues like putting prefix " Dr" infront of their name in internship or after getting degree.
all tactics to mislead students from real issue. It doesnt matter whether they write PharmD or doctor of pharmacy in degree, ultimately you remain a pharmacist.
My opinion:The real issue is they dont want to add the mentioned subjects in other universities except in deemed universities like JSS and Manipal, who dont depend on others to add any subjects in their syllabus. Thats why their fees is exceptionally high in comparison to other universities and colleges . For pharmD(PB) 3 yrs course ,they ask 9 lakhs as fees. And Dr B.Suresh who is South Indian himself, had his whole schooling, gradution and postgraduation in Mysore,South India, is also Principal of the JSS college as well as Chairman of JSS univ,who also happens to be the PCI president.They want to create monopoly and enjoy the exclusive status of colleges/universities with advantages of having additional subjects. The more delay it gets for years,the more these exclusive universities enjoy this benefit.Quote:You can tell monopoly is an old game because there is a luxary tax and rich people can go to jail.Quote : Power corrupts, absolute power absolutely.

Tuesday 6 February 2024

High-Risk Drugs

High-Risk Drugs

"High risk medicines are those medicines that have a high risk of causing significant patient harm or death when used in error.- Google search

Although errors may or may not be more common than with other medicines, the consequences of errors with these medicines can be more devastating" - Google search.

"A – Antimicrobials

P – Potassium and other electrolytes, psychotropic medications

I – Insulin

N – Narcotics, opioids and sedatives

C – Chemotherapeutic agents

H – Heparin and other anticoagulants

S – Safer systems (e.g. safe administration of liquid medications using oral syringes)

Methods to reduce error include strategies such as:

👉 improving access to information about these drugs
👉 limiting access to high risk medications
👉 using Tallman* lettering to differentiate high risk medications
using auxiliary labels and automated alerts
👉 standardising the prescription, storage, preparation, and administration of these products."
------------
*Tallman lettering:
1.acetaZOLAMIDE vs. acetoHEXAMIDE.

2. buPROPion vs. busPIRone.

3.chlorproMAZINE vs. chlorproPAMIDE.

5.clomiPHENE vs. clomiPRAMINE.

6. cycloSERINE vs. cycloSPORINE."
- Google search.

Pharmacists should recollect their lessons on Routes of Administration, Times of Administration, LASA drug names and Importance of Administration by Medical attendant or under Medical supervision.

Identifying and self regulating them by Retail Pharmacists looks highly imminent Now in Public Interest.

Attn. #Pharmacists &
          #DrugsInspectors

Tuesday 30 January 2024

DTAB proposed to GoI an amendment to Sch K to circumvent all such judicial orders. Our representatives from PCI and IPA (Big) agreed to it for a cup of Tea!

DTAB proposed to GoI an amendment to Sch K to circumvent all such judicial orders.

Our representatives from PCI and IPA (Big) agreed to it for a cup of Tea!

Dispensing Of Medicines Under Doctor Without Pharmacist: High Court Stays Government Order

By Farhat NasimPublished On 15 Dec 2019 3:28 PM  |  Updated On 15 Dec 2019 3:28 PM

The court, subsequently held that the orders were unsustainable under the law and ordered the government to ensure that medicines were dispensed through qualified pharmacists

Kochi: The Kerala Government's order that approved dispensing of drugs under the supervision of medical practitioner in the absence of pharmacists at the government hospital pharmacies has come to a halt as the High Court recently issued a stay order.

The stay order was issued by Justice P B Suresh following a petition filed by All Kerala Pharmacists Union (AKPU), who submitted that only a registered pharmacist shall dispense any medicine as per Section 42 of Pharmacy Act, 1948.

The pharmacists union saw red after the state government issued an order that empowered the doctors/medical officers to dispense medicines under his/her direct supervision in case the pharmacist is absent from the hospital pharmacy or if he leaves the pharmacy. This was issued by the government in complying with the verdict passed by the high court in 2017. The 2017 case related to a statement by the Director of Health Services (DHS) allowing distribution of medicines through unqualified pharmacists.

As per a recent TOI report, the petitioner contended that in 2013, DHS had issued a circular pointing out that unqualified persons performing duties of pharmacists in government hospitals are in violation of the law. When Pharmacy Practice Regulations, 2015 came into being, the government issued a circular for its strict implementation and to prevent dispensing of medicines by unqualified persons.

However, in 2016, the DHS issued 2 orders for distributing medicines for non-communicable diseases (NCDs) to sub-centre clinics and allowing junior public health nurses to dispense NCD medicines, the petitioner added.

After hearing the entire case, the court subsequently held that the orders were unsustainable under the law and ordered the government to ensure that medicines were dispensed through qualified pharmacists, reports TOI.